Now Available: China Follicle-Stimulating Hormone (FSH) Market, 2010-2019.
[USPRwire, Fri Aug 14 2015] According to WHO's evaluation, one in seven couples suffer from fertility which influences about 10%-15% of the world population. According to a survey, the number of patients with fertility accounts for 10% of married people, being double of 4.8% in 1984. The incidence of fertility in young people has increased and it is 15%-20% among women of childbearing age. For patients with hypothalamic-pituitary dysfunction including polycystic ovary syndrome, FSH can promote follicular development while in the case of blocked fallopian tube, unexplained fertility and fertility caused by male factor, FSH can do so in the assistive technology used to conceive the child.
FSH brought in a global sales value of over USD 1.2 billion in 2013 to which Gonal-f (FSHa) made by Merck Serono contributed USD 813 million with a market share of 63% while Puregon (FSHB) of Merck contributed USD 481 million with a market share of 37%. FSH develops fast after entering China, annual sales value rising from less than CNY 2 million in 2006 to CNY 215 million in 2014 and CAGR during this period reaching 84.2%. Merck Serono (rhFSHa), Livzon Pharmaceutical Group Co., Ltd (UFSH), IBSA (UFSH) and Organon (rhFSHB) dominate the Chinese market, among which Livzon Pharmaceutical Group Co., Ltd has the largest market share of about 59% for sales value in 2014.
As the number of patients suffering from infertility is huge in China, FSH has good market prospects.
Full Report Details at
Readers can get at least the following information from this report:
* market size of FSH in China
* competitive landscape of FSH in Chinese market
* price of FSH made by different enterprises in China
* market outlook of FSH in China
The author suggests the following groups of people purchase this report:
* manufacturers of endocrine regulator
* investors/ research institutions interested in Chinese medicine market
* any interest in the Chinese medicine market, please contact CRI for customized survey service
Companies Mentioned in this Report: Livzon Pharmaceutical Group Co., Ltd, Merck Serono, IBSA Institut Biochimique SA
Copyright [c] 2015 USPRwire Provided by SyndiGate Media Inc. ( Syndigate.info ).
|Printer friendly Cite/link Email Feedback|
|Date:||Aug 14, 2015|
|Previous Article:||Now Available: A. Menarini Industrie Farmaceutiche Riunite Srl - Product Pipeline Review - 2015.|
|Next Article:||Pompe Disease Global Clinical Trials Review, H1, 2015 - New Market Research Report.|